United States Spinal Muscular Atrophy Medicine Market Report 2018

January 2018 | 112 pages | ID: UCD375EF498EN
QYResearch

Abstracts

In this report, the United States Spinal Muscular Atrophy Medicine market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Spinal Muscular Atrophy Medicine in these regions, from 2013 to 2025 (forecast).

United States Spinal Muscular Atrophy Medicine market competition by top manufacturers/players, with Spinal Muscular Atrophy Medicine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Astellas Pharma Inc.
• AveXis, Inc.
• Bioblast Pharma Ltd.
• Cytokinetics, Inc. 24
• F. Hoffmann-La Roche Ltd.
• Genethon
• Genzyme Corporation
• GMP-Orphan SAS
• Ionis Pharmaceuticals, Inc.
• Longevity Biotech, Inc
• Neurodyn Inc.
• Neurotune AG
• Novartis AG
• Sarepta Therapeutics, Inc.
• Voyager Therapeutics, Inc.
• Vybion, Inc.
• WAVE Life Sciences Ltd.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• LMI-070
• ND-602
• NT-1654
• Nusinersen
• NXD-30001
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital
• Clinic
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Spinal Muscular Atrophy Medicine Market Report 2018

1 SPINAL MUSCULAR ATROPHY MEDICINE OVERVIEW

1.1 Product Overview and Scope of Spinal Muscular Atrophy Medicine
1.2 Classification of Spinal Muscular Atrophy Medicine by Product Category
  1.2.1 United States Spinal Muscular Atrophy Medicine Market Size (Sales Volume) Comparison by Type (2013-2025)
  1.2.2 United States Spinal Muscular Atrophy Medicine Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
  1.2.3 LMI-070
  1.2.4 ND-602
  1.2.5 NT-1654
  1.2.6 Nusinersen
  1.2.7 NXD-30001
  1.2.8 Others
1.3 United States Spinal Muscular Atrophy Medicine Market by Application/End Users
  1.3.1 United States Spinal Muscular Atrophy Medicine Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Others
1.4 United States Spinal Muscular Atrophy Medicine Market by Region
  1.4.1 United States Spinal Muscular Atrophy Medicine Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 The West Spinal Muscular Atrophy Medicine Status and Prospect (2013-2025)
  1.4.3 Southwest Spinal Muscular Atrophy Medicine Status and Prospect (2013-2025)
  1.4.4 The Middle Atlantic Spinal Muscular Atrophy Medicine Status and Prospect (2013-2025)
  1.4.5 New England Spinal Muscular Atrophy Medicine Status and Prospect (2013-2025)
  1.4.6 The South Spinal Muscular Atrophy Medicine Status and Prospect (2013-2025)
  1.4.7 The Midwest Spinal Muscular Atrophy Medicine Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Spinal Muscular Atrophy Medicine (2013-2025)
  1.5.1 United States Spinal Muscular Atrophy Medicine Sales and Growth Rate (2013-2025)
  1.5.2 United States Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2013-2025)

2 UNITED STATES SPINAL MUSCULAR ATROPHY MEDICINE MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Spinal Muscular Atrophy Medicine Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Spinal Muscular Atrophy Medicine Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Spinal Muscular Atrophy Medicine Average Price by Players/Suppliers (2013-2018)
2.4 United States Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends
  2.4.1 United States Spinal Muscular Atrophy Medicine Market Concentration Rate
  2.4.2 United States Spinal Muscular Atrophy Medicine Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Spinal Muscular Atrophy Medicine Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES SPINAL MUSCULAR ATROPHY MEDICINE SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Spinal Muscular Atrophy Medicine Sales and Market Share by Region (2013-2018)
3.2 United States Spinal Muscular Atrophy Medicine Revenue and Market Share by Region (2013-2018)
3.3 United States Spinal Muscular Atrophy Medicine Price by Region (2013-2018)

4 UNITED STATES SPINAL MUSCULAR ATROPHY MEDICINE SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)

4.1 United States Spinal Muscular Atrophy Medicine Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Spinal Muscular Atrophy Medicine Revenue and Market Share by Type (2013-2018)
4.3 United States Spinal Muscular Atrophy Medicine Price by Type (2013-2018)
4.4 United States Spinal Muscular Atrophy Medicine Sales Growth Rate by Type (2013-2018)

5 UNITED STATES SPINAL MUSCULAR ATROPHY MEDICINE SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Spinal Muscular Atrophy Medicine Sales and Market Share by Application (2013-2018)
5.2 United States Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 UNITED STATES SPINAL MUSCULAR ATROPHY MEDICINE PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Astellas Pharma Inc.
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2013-2018)
  6.1.4 Main Business/Business Overview
6.2 AveXis, Inc.
  6.2.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2013-2018)
  6.2.4 Main Business/Business Overview
6.3 Bioblast Pharma Ltd.
  6.3.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2013-2018)
  6.3.4 Main Business/Business Overview
6.4 Cytokinetics, Inc.
  6.4.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2013-2018)
  6.4.4 Main Business/Business Overview
6.5 F. Hoffmann-La Roche Ltd.
  6.5.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2013-2018)
  6.5.4 Main Business/Business Overview
6.6 Genethon
  6.6.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2013-2018)
  6.6.4 Main Business/Business Overview
6.7 Genzyme Corporation
  6.7.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2013-2018)
  6.7.4 Main Business/Business Overview
6.8 GMP-Orphan SAS
  6.8.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2013-2018)
  6.8.4 Main Business/Business Overview
6.9 Ionis Pharmaceuticals, Inc.
  6.9.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2013-2018)
  6.9.4 Main Business/Business Overview
6.10 Longevity Biotech, Inc
  6.10.2 Spinal Muscular Atrophy Medicine Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2013-2018)
  6.10.4 Main Business/Business Overview
6.11 Neurodyn Inc.
6.12 Neurotune AG
6.13 Novartis AG
6.14 Sarepta Therapeutics, Inc.
6.15 Voyager Therapeutics, Inc.
6.16 Vybion, Inc.
6.17 WAVE Life Sciences Ltd.

7 SPINAL MUSCULAR ATROPHY MEDICINE MANUFACTURING COST ANALYSIS

7.1 Spinal Muscular Atrophy Medicine Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Spinal Muscular Atrophy Medicine Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Spinal Muscular Atrophy Medicine Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES SPINAL MUSCULAR ATROPHY MEDICINE MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

11.1 United States Spinal Muscular Atrophy Medicine Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Spinal Muscular Atrophy Medicine Sales Volume Forecast by Type (2018-2025)
11.3 United States Spinal Muscular Atrophy Medicine Sales Volume Forecast by Application (2018-2025)
11.4 United States Spinal Muscular Atrophy Medicine Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Spinal Muscular Atrophy Medicine
Figure United States Spinal Muscular Atrophy Medicine Market Size (K Pcs) by Type (2013-2025)
Figure United States Spinal Muscular Atrophy Medicine Sales Volume Market Share by Type (Product Category) in 2017
Figure LMI-070 Product Picture
Figure ND-602 Product Picture
Figure NT-1654 Product Picture
Figure Nusinersen Product Picture
Figure NXD-30001 Product Picture
Figure Others Product Picture
Figure United States Spinal Muscular Atrophy Medicine Market Size (K Pcs) by Application (2013-2025)
Figure United States Sales Market Share of Spinal Muscular Atrophy Medicine by Application in 2017
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Spinal Muscular Atrophy Medicine Market Size (Million USD) by Region (2013-2025)
Figure The West Spinal Muscular Atrophy Medicine Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Spinal Muscular Atrophy Medicine Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Spinal Muscular Atrophy Medicine Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Spinal Muscular Atrophy Medicine Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Spinal Muscular Atrophy Medicine Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Spinal Muscular Atrophy Medicine Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Spinal Muscular Atrophy Medicine Sales (K Pcs) and Growth Rate (2013-2025)
Figure United States Spinal Muscular Atrophy Medicine Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Spinal Muscular Atrophy Medicine Market Major Players Product Sales Volume (K Pcs) (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Sales (K Pcs) of Key Players/Suppliers (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Spinal Muscular Atrophy Medicine Sales Share by Players/Suppliers
Figure 2017 United States Spinal Muscular Atrophy Medicine Sales Share by Players/Suppliers
Figure United States Spinal Muscular Atrophy Medicine Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Spinal Muscular Atrophy Medicine Revenue Share by Players/Suppliers
Figure 2017 United States Spinal Muscular Atrophy Medicine Revenue Share by Players/Suppliers
Table United States Market Spinal Muscular Atrophy Medicine Average Price (USD/Pcs) of Key Players/Suppliers (2013-2018)
Figure United States Market Spinal Muscular Atrophy Medicine Average Price (USD/Pcs) of Key Players/Suppliers in 2017
Figure United States Spinal Muscular Atrophy Medicine Market Share of Top 3 Players/Suppliers
Figure United States Spinal Muscular Atrophy Medicine Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Spinal Muscular Atrophy Medicine Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Spinal Muscular Atrophy Medicine Product Category
Table United States Spinal Muscular Atrophy Medicine Sales (K Pcs) by Region (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Sales Share by Region (2013-2018)
Figure United States Spinal Muscular Atrophy Medicine Sales Share by Region (2013-2018)
Figure United States Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2017
Table United States Spinal Muscular Atrophy Medicine Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Revenue Share by Region (2013-2018)
Figure United States Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2013-2018)
Figure United States Spinal Muscular Atrophy Medicine Revenue Market Share by Region in 2017
Table United States Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Region (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Sales Share by Type (2013-2018)
Figure United States Spinal Muscular Atrophy Medicine Sales Share by Type (2013-2018)
Figure United States Spinal Muscular Atrophy Medicine Sales Market Share by Type in 2017
Table United States Spinal Muscular Atrophy Medicine Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Spinal Muscular Atrophy Medicine by Type (2013-2018)
Figure Revenue Market Share of Spinal Muscular Atrophy Medicine by Type in 2017
Table United States Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Types (2013-2018)
Figure United States Spinal Muscular Atrophy Medicine Sales Growth Rate by Type (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Sales (K Pcs) by Application (2013-2018)
Table United States Spinal Muscular Atrophy Medicine Sales Market Share by Application (2013-2018)
Figure United States Spinal Muscular Atrophy Medicine Sales Market Share by Application (2013-2018)
Figure United States Spinal Muscular Atrophy Medicine Sales Market Share by Application in 2017
Table United States Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2013-2018)
Figure United States Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2013-2018)
Table Astellas Pharma Inc. Basic Information List
Table Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales Growth Rate (2013-2018)
Figure Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales Market Share in United States (2013-2018)
Figure Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Revenue Market Share in United States (2013-2018)
Table AveXis, Inc. Basic Information List
Table AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure AveXis, Inc. Spinal Muscular Atrophy Medicine Sales Growth Rate (2013-2018)
Figure AveXis, Inc. Spinal Muscular Atrophy Medicine Sales Market Share in United States (2013-2018)
Figure AveXis, Inc. Spinal Muscular Atrophy Medicine Revenue Market Share in United States (2013-2018)
Table Bioblast Pharma Ltd. Basic Information List
Table Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales Growth Rate (2013-2018)
Figure Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales Market Share in United States (2013-2018)
Figure Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Revenue Market Share in United States (2013-2018)
Table Cytokinetics, Inc. 24 Basic Information List
Table Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales Growth Rate (2013-2018)
Figure Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales Market Share in United States (2013-2018)
Figure Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Revenue Market Share in United States (2013-2018)
Table F. Hoffmann-La Roche Ltd. Basic Information List
Table F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales Growth Rate (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales Market Share in United States (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Revenue Market Share in United States (2013-2018)
Table Genethon Basic Information List
Table Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Genethon Spinal Muscular Atrophy Medicine Sales Growth Rate (2013-2018)
Figure Genethon Spinal Muscular Atrophy Medicine Sales Market Share in United States (2013-2018)
Figure Genethon Spinal Muscular Atrophy Medicine Revenue Market Share in United States (2013-2018)
Table Genzyme Corporation Basic Information List
Table Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Genzyme Corporation Spinal Muscular Atrophy Medicine Sales Growth Rate (2013-2018)
Figure Genzyme Corporation Spinal Muscular Atrophy Medicine Sales Market Share in United States (2013-2018)
Figure Genzyme Corporation Spinal Muscular Atrophy Medicine Revenue Market Share in United States (2013-2018)
Table GMP-Orphan SAS Basic Information List
Table GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales Growth Rate (2013-2018)
Figure GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales Market Share in United States (2013-2018)
Figure GMP-Orphan SAS Spinal Muscular Atrophy Medicine Revenue Market Share in United States (2013-2018)
Table Ionis Pharmaceuticals, Inc. Basic Information List
Table Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales Growth Rate (2013-2018)
Figure Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales Market Share in United States (2013-2018)
Figure Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Revenue Market Share in United States (2013-2018)
Table Longevity Biotech, Inc Basic Information List
Table Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales Growth Rate (2013-2018)
Figure Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales Market Share in United States (2013-2018)
Figure Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Revenue Market Share in United States (2013-2018)
Table Neurodyn Inc. Basic Information List
Table Neurotune AG Basic Information List
Table Novartis AG Basic Information List
Table Sarepta Therapeutics, Inc. Basic Information List
Table Voyager Therapeutics, Inc. Basic Information List
Table Vybion, Inc. Basic Information List
Table WAVE Life Sciences Ltd. Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Spinal Muscular Atrophy Medicine
Figure Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
Figure Spinal Muscular Atrophy Medicine Industrial Chain Analysis
Table Raw Materials Sources of Spinal Muscular Atrophy Medicine Major Players/Suppliers in 2017
Table Major Buyers of Spinal Muscular Atrophy Medicine
Table Distributors/Traders List
Figure United States Spinal Muscular Atrophy Medicine Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure United States Spinal Muscular Atrophy Medicine Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Spinal Muscular Atrophy Medicine Price (USD/Pcs) Trend Forecast (2018-2025)
Table United States Spinal Muscular Atrophy Medicine Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Spinal Muscular Atrophy Medicine Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Spinal Muscular Atrophy Medicine Sales Volume (K Pcs) Forecast by Type in 2025
Table United States Spinal Muscular Atrophy Medicine Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Spinal Muscular Atrophy Medicine Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Spinal Muscular Atrophy Medicine Sales Volume (K Pcs) Forecast by Application in 2025
Table United States Spinal Muscular Atrophy Medicine Sales Volume (K Pcs) Forecast by Region (2018-2025)
Table United States Spinal Muscular Atrophy Medicine Sales Volume Share Forecast by Region (2018-2025)
Figure United States Spinal Muscular Atrophy Medicine Sales Volume Share Forecast by Region (2018-2025)
Figure United States Spinal Muscular Atrophy Medicine Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources